GlassScriptPhysician profile
Sapna Patel
NPI 1992842280
$186,165.19
in general payments reported to CMS, 2019-2025
17 companies · $27K in 2025
The $27K reported for 2025 was more than what 91% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $21.90 · 2021: $2,171 · 2022: $11K · 2023: $45K · 2024: $86K · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $76K · Travel and Lodging: $46K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $33K · Food and Beverage: $2,846.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $76,466.50 |
| Travel and Lodging | $46,095.88 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $33,345.00 |
| Food and Beverage | $2,846.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $123,232.90 | 2019-2025 | Keytruda |
| E.R. Squibb & Sons, L.L.C. | $18,058.08 | 2022-2025 | Opdivo, Opdualag |
| Novartis Pharmaceuticals Corporation | $11,299.55 | 2022-2024 | |
| Sun Pharmaceutical Industries INC. | $9,128.20 | 2025 | |
| Array Biopharma INC | $7,900.38 | 2023-2025 | Braftovi, Mektovi |
| Hexal Ag | $7,425.00 | 2024 | |
| Trisalus Life Sciences, INC. | $4,748.72 | 2021-2024 | Trinav Infusion System |
| Daiichi Sankyo INC. | $2,079.01 | 2025 | |
| Pfizer INC. | $1,957.27 | 2024 | |
| Iovance Biotherapeutics, INC. | $137.38 | 2024 | Amtagvi |
| Regeneron Healthcare Solutions, INC. | $67.59 | 2022 | |
| Mannkind Corporation | $64.74 | 2023 | Afrezza |
| Lilly USA, LLC | $24.99 | 2024 | Jardiance |
| Vifor Pharma, INC. | $23.82 | 2025 | Veltassa |
| Amgen INC. | $17.56 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sapna Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.